RT Book, Section
A1 Law, Rebecca M.
A1 Gulliver, Wayne P.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1153075009
T1 Psoriasis
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1153075009
RD 2022/05/29
AB Content  UpdateApril  18,  2018American  College  of  Rheumatology  White  Paper  on  Biosimilars:  The  American  College  of  Rheumatology  (ACR)  published  a  white  paper  that  reviews  the  scientific,  clinical,  economic,  and  prescribing  issues  related  to  use  of  biosimilars.  A  "biosimilar"  is  a  biologic  product  that  is  highly  similar  to  an  approved  reference  (or  originator)  biologic  product  and  has  no  clinically  meaningful  differences  in  efficacy,  adverse  effects,  or  immunogenicity  compared  to  the  reference  product.  Based  on  the  outcomes  of  rigorous  regulatory  requirements,  the  ACR  white  paper  asserts  that  patients  and  healthcare  providers  should  have  confidence  that  an  approved  biosimilar  should  produce  clinical  outcomes  comparable  to  those  achieved  with  its  reference  product.  The  paper  encourages  healthcare  providers  to  incorporate  biosimilars  into  their  practices  where  appropriate  with  the  goal  of  continued  delivery  of  high-quality  health  care  at  lower  cost  to  individual  patients.